Abstract
PurposeTo compare [18F]-fluorodeoxyglucose (FDG) and [18F]-sodium fluoride (NaF) positron emission tomography/computed tomography (PET/CT) with whole-body magnetic resonance with diffusion-weighted imaging (WB-MRI), for endocrine therapy response prediction at 8 weeks in bone-predominant metastatic breast cancer.Patients and methodsThirty-one patients scheduled for endocrine therapy had up to five bone metastases measured [FDG, NaF PET/CT: maximum standardized uptake value (SUVmax); WB-MRI: median apparent diffusion coefficient (ADCmed)] at baseline and 8 weeks. To detect the flare phenomenon, a 12-week NaF PET/CT was also performed if 8-week SUVmax increased. A 25% parameter change differentiated imaging progressive disease (PD) from non-PD and was compared to a 24-week clinical reference standard and progression-free survival (PFS).ResultsTwenty-two patients (median age, 58.6 years, range, 40–79 years) completing baseline and 8-week imaging were included in the final analysis.Per-patient % change in NaF SUVmax predicted 24-week clinical PD with sensitivity, specificity and accuracy of 60, 73.3, and 70%, respectively. For FDG SUVmax the results were 0, 100, and 76.2% and for ADCmed, 0, 100 and 72.2%, respectively.PFS < 24 weeks was associated with % change in SUVmax (NaF: 41.7 vs. 0.7%, p = 0.039; FDG: − 4.8 vs. − 28.6%, p = 0.005) but not ADCmed (− 0.5 vs. 10.1%, p = 0.098). Interlesional response heterogeneity occurred in all modalities and NaF flare occurred in seven patients.ConclusionsFDG PET/CT and WB-MRI best predicted clinical non-PD and both FDG and NaF PET/CT predicted PFS < 24 weeks. Lesional response heterogeneity occurs with all modalities and flare is common with NaF PET/CT.
Highlights
Bone metastases in patients with advanced breast cancer are common, occurring in at least 70% of patients with advanced disease, and cause significant morbidity [1]
We have shown in this cohort of bone-predominant metastatic breast cancer patients treated with endocrine therapy that changes in parameters that reflect tumor cellularity (DWI), tumor glucose metabolism (FDG positron emission tomography/ computed tomography (PET/computed tomography (CT))), and the bone microenvironment (NaF PET/CT), can be detected and quantified
Neither WB-magnetic resonance imaging (MRI) nor FDG PET/CT predicted progressive disease (PD) at this early 8-week time point. Both FDG PET/CT and WB-MRI primarily reflect tumor cell effects and while these demonstrated > 25% changes in less than 8 weeks in many responding metastases, the biological changes associated with tumor progression were not of sufficient magnitude to be detected this early at this threshold, implying a non-linear relationship between changes in image parameters and clinical PD
Summary
Bone metastases in patients with advanced breast cancer are common, occurring in at least 70% of patients with advanced disease, and cause significant morbidity [1]. Patients with breast cancer and bone metastases have a relatively long survival compared to other cancers and coupled with the associated morbidity, there are significant implications for healthcare costs [2, 3]. Eur J Nucl Med Mol Imaging (2019) 46:821–830 scan is considered to have poor sensitivity and specificity for detecting early response or non-response [7]. This means that without an objective early measure of non-response, patients with bone-predominant metastatic disease may continue with ineffective treatment longer than necessary, delaying therapeutic transition to second or third-line treatment and exposing them to unnecessary treatment-related side effects
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
